Related Experiment Video
Updated: Feb 2, 2026

Laparoscopic Radical Left Pancreatectomy for Pancreatic Cancer: Surgical Strategy and Technique Video
Published on: June 6, 2020
Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions
Elaine Tan1, Bassel El-Rayes2,3
1Department of Internal Medicine, Emory University School of Medicine, 100 Woodruff Circle Suite, 327, Atlanta, GA, 30322, USA. estan@emory.edu.
Background:
Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the most aggressive and lethal diseases in the world. The success of immunotherapy in other types of malignancy has led to further trials to understand better the role of immunotherapy in PDAC. However, initial studies with immunotherapy, namely, the checkpoint inhibitors, in PDAC have not been met with the same outcomes. The purpose of this review is to identify and discuss the various resistance mechanisms of PDAC to immunotherapy (pancreatic stroma, genetic predisposition/epigenetics, and the immune inhibitory cells, cytokines, soluble factors, and enzymes that comprise the tumor microenvironment) and the solutions currently being studied to overcome them.
Conclusions:
Various preclinical and early clinical studies have shown that immunotherapy, especially checkpoint inhibitors, in PDAC may be efficacious as part of a multi-modal treatment, in combination with other therapies that target these resistance mechanisms. Several clinical trials are ongoing to explore this concept further.
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanisms of Retrovirus-induced Cancers
Ideal Solutions
General Properties of Solutions

